Ceftriaxone-Induced Immune Hemolytic Anemia.
ceftriaxone
immune hemolytic anemia
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
17 Jun 2020
17 Jun 2020
Historique:
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
24
7
2020
Statut:
epublish
Résumé
Ceftriaxone is a commonly used antibiotic in hospitals for the treatment of pneumonia, urinary tract infection, bacteremia, meningitis, skin, and soft tissue infection. It can be associated with common allergic reactions like skin rash, itching, and, rarely, angioedema. Ceftriaxone-induced immune hemolytic anemia (IHA) is a rare and potentially fatal complication if not identified and managed in time. We report a case of ceftriaxone-induced IHA in a young woman.
Identifiants
pubmed: 32699660
doi: 10.7759/cureus.8660
pmc: PMC7370697
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e8660Informations de copyright
Copyright © 2020, Singh et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2019 Aug 15;381(7):647-654
pubmed: 31412178
Transfusion. 2007 Apr;47(4):697-702
pubmed: 17381629
Transfusion. 2012 Mar;52(3):602-12
pubmed: 21880048
Transfus Med Hemother. 2015 Sep;42(5):333-9
pubmed: 26696803
Semin Hematol. 2005 Jul;42(3):137-44
pubmed: 16041663
Eur J Haematol. 2019 Feb;102(2):157-162
pubmed: 30347480